Description
Description
The prostate is a male-specific gonadal organ. Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of urination disorder in middle-aged and elderly men. Epidemiologically, the incidence of BPH increases with age. BPH usually occurs after the age of 40. The incidence in men aged above 60 is higher than 50% and the incidence in men aged above 80 is 83%. Like histologic appearance, symptoms such as dysuria also increase with age. Patients with BPH account for 8% to 11% of urological inpatients, with incidence second only to that of lithangiuria. As the Chinese population ages, BPH will affect the health of more elderly people.
Finasteride is a 4-nitrosteroid hormone compound, a specific type II 5α-reductase inhibitor developed by U.S. company MSD. Since Jun. 1992 when it was approved by the FDA to be sold under trade name Proscar, it has been registered and launched in over 100 countries and regions around the world. After MSD launched Finasteride in China, many Chinese pharmaceutical companies began to develop generic Finasteride. In China, Finasteride is used to treat and control BPH and prevent urinary system events, reduce the risk of acute urinary retention and reduce the risks of transurethral resection of the prostate (TURP) and prostatectomy.
According to CRI’s market survey, in 2003, Zhejiang Xianju Pharmaceutical Co., Ltd. became the first company that was approved by the CFDA to launch generic Finasteride in China. Later, other companies launched their generic Finasteride products in succession. At the end of 2018, about 20 companies were selling Finasteride in China. The brand-name Finasteride by MSD still took up a market share of more than 90%. The sales value of Finasteride kept rising after the drug was launched in China. In 2017, it reached CNY 248 million, representing a CAGR of about 2.00% from 2013 to 2017.
CRI expects that as the Chinese population ages, the incidence of BPH and the number of patients with BPH increase in China and the indications for Finasteride expand, China’s Finasteride market will continue to grow.
Topics Covered:
– Incidence of benign prostatic hyperplasia in China
– Status of China’s Finasteride market
– Competition on China’s Finasteride market
– Major Finasteride manufacturers in China
– Prices of Finasteride in China
– Major factors influencing the development of China’s Finasteride market
– Prospect of China’s Finasteride market from 2019 to 2023
Table of Contents
Table of Contents
1 Relevant Concepts of Finasteride
1.1 Indications for Finasteride
1.2 Development of Finasteride in China
1.3 Patents and Government Approval on Finasteride in China
2 Sales of Finasteride in China, 2013-2017
2.1 Sales Value of Finasteride
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Finasteride
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Finasteride by Dosage Form in China, 2013-2017
2.3.1 Sales of Finasteride Tablets
2.3.2 Sales of Finasteride Capsules
3 Analysis on Major Finasteride Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Finasteride Manufacturers in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 MSD
3.2.1 Enterprise Profile
3.3.2 Sales of Finasteride by MSD in China
3.3 Guangdong Rongtai Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Finasteride by Guangdong Rongtai Pharmaceutical Co., Ltd. in China
3.4 China Meheco Topfond Pharma Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Finasteride in by China Meheco Topfond Pharma Co., Ltd. in China
3.5 China Resources Saike Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Finasteride in by China Resources Saike Pharmaceutical Co., Ltd. in China
3.6 Zhejiang Xianju Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Finasteride by Zhejiang Xianju Pharmaceutical Co., Ltd. in China
4 Prices of Finasteride in China, 2017-2018
4.1 MSD (Propecia)
4.2 Guangdong Rongtai Pharmaceutical Co., Ltd.
4.3 China Meheco Topfond Pharma Co., Ltd. (Qiyue)
4.4 China Resources Saike Pharmaceutical Co., Ltd. (Kabo)
4.5 Zhejiang Xianju Pharmaceutical Co., Ltd.
5 Prospect of China's Finasteride Market, 2019-2023
5.1 Major Factors Influencing Development of China's Finasteride Market
5.1.1 Favorable Factors
5.1.2 Unfavorable Factors
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
Selected Charts
Chart Patents on Finasteride in China
Chart Government Approval on Finasteride in China
Chart Sales Value of Finasteride in China, 2013-2017
Chart Sales Value of Finasteride in Parts of China, 2013-2017
Chart Sales Volume of Finasteride in China, 2013-2017
Chart Sales Volume of Finasteride in Parts of China, 2013-2017
Chart Sales Value of Finasteride Tablets in China, 2013-2017
Chart Sales Volume of Finasteride Tablets in China, 2013-2017
Chart Sales Value of Finasteride Capsules in China, 2013-2017
Chart Market Share of Top 5 Finasteride Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Finasteride Manufacturers by Sales Volume in China, 2013-2017
Chart Profile of MSD
Chart Sales Value of Finasteride by MSD in China, 2013-2017
Chart Sales Volume of Finasteride by MSD in China, 2013-2017
Chart Profile of Guangdong Rongtai Pharmaceutical Co., Ltd.
Chart Sales Value of Finasteride by Guangdong Rongtai Pharmaceutical Co., Ltd. in China, 2013-2017
Chart Profile of China Meheco Topfond Pharma Co., Ltd.
Chart Profile of China Resources Saike Pharmaceutical Co., Ltd.
Chart Sales Value of Finasteride by China Resources Saike Pharmaceutical Co., Ltd. in China, 2013-2017
Chart Profile of Zhejiang Xianju Pharmaceutical Co., Ltd.
Chart Prices of Finasteride by MSD in Parts of China, 2017-2018
Chart Prices of Finasteride by Guangdong Rongtai Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
Chart Prices of Finasteride by China Meheco Topfond Pharma Co., Ltd. in Parts of China, 2017-2018
Chart Forecast on Sales Value of Finasteride in China, 2019-2023
